Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol

BACKGROUND: Between 30 and 50% of patients with major depressive disorder (MDD) do not respond sufficiently to antidepressant regimens. The conventional pharmacological treatments predominantly target serotonergic brain signaling but better tools to predict treatment response and identify relevant s...

Descripción completa

Detalles Bibliográficos
Autores principales: Köhler-Forsberg, Kristin, Jorgensen, Anders, Dam, Vibeke H., Stenbæk, Dea Siggaard, Fisher, Patrick M., Ip, Cheng-Teng, Ganz, Melanie, Poulsen, Henrik Enghusen, Giraldi, Annamaria, Ozenne, Brice, Jørgensen, Martin Balslev, Knudsen, Gitte Moos, Frokjaer, Vibe Gedsoe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391965/
https://www.ncbi.nlm.nih.gov/pubmed/32792991
http://dx.doi.org/10.3389/fpsyt.2020.00641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391965/
https://www.ncbi.nlm.nih.gov/pubmed/32792991
http://dx.doi.org/10.3389/fpsyt.2020.00641

Ejemplares similares